Scarica l'app Stockscreener
88.98
9.74%
-9.60
Dopo l'orario di chiusura:
88.75
-0.23
-0.26%
Precedente Chiudi:
$98.58
Aprire:
$109.66
Volume 24 ore:
817.65K
Relative Volume:
3.75
Capitalizzazione di mercato:
$1.05B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.82%
1M Prestazione:
+6.28%
6M Prestazione:
+255.21%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$84.25
$112.00
Intervallo di 1 settimana:
$84.25
$112.00
Portata 52W:
$11.17
$112.00
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
88.98 | 1.17B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella Therapeutics stock price target raised to $192 at BTIG on positive trial data - Investing.com UK
Palvella Therapeutics stock price target raised to $143 on positive trial data - Investing.com Canada
Truist Securities raises Palvella Therapeutics stock price target to $190 - Investing.com
Palvella Therapeutics stock maintains Buy rating at Clear Street on pipeline progress - Investing.com UK
Palvella Therapeutics stock price target raised to $200 from $190 at H.C. Wainwright - Investing.com Canada
Palvella Therapeutics stock price target raised to $212 from $122 at Lucid Capital - Investing.com Canada
Palvella stock price target raised to $200 from $120 at Oppenheimer - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighHere's What Happened - MarketBeat
'Not for everybody but it's a classic biotech setup': Baral on Palvella Therapeutics - BNN Bloomberg
Palvella Therapeutics stock hits 52-week high at 110.34 USD - Investing.com
Palvella Therapeutics stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com UK
Palvella Therapeutics Reports Positive Topline Phase 2 Data for Qtorin Gel in Rare Skin Condition - marketscreener.com
Palvella Therapeutics Reports Positive Phase 2 Study Results - TipRanks
Palvella Therapeutics announces positive topline results from phase 2 Toiva clinical trial of Qtorin - marketscreener.com
Palvella Therapeutics Announces Positive Phase 2 TOIVA Study Results - TradingView — Track All Markets
Palvella Therapeutics Announces Positive Topline Results - GlobeNewswire
Frazier Life Sciences Management L.P. Has $16.28 Million Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Is Longfor Group Holdings Limited RLF a good long term investmentFederal Reserve Announcements & Small Investment Big Gains - earlytimes.in
Palvella Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Palvella Therapeutics (PVLA) price target increased by 15.61% to 133.70 - MSN
XTX Topco Ltd Acquires Shares of 17,701 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Palvella Therapeutics initiated with a buy at Craig-Hallum - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 8% HigherStill a Buy? - MarketBeat
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Craig Hallum - MarketBeat
Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70 - Nasdaq
Clear Street Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
BTIG Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street Initiates Coverage on PVLA with a 'Buy' Rating | PV - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target - marketscreener.com
BTIG initiates coverage on Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Craig-Hallum Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street initiates Palvella Therapeutics stock with Buy rating, $200 target - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock beat revenue estimates2025 Price Targets & Long-Term Investment Growth Plans - Newser
How Palvella Therapeutics Inc. (PI6) stock compares with top peersJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Can Palvella Therapeutics Inc. stock sustain revenue growth2025 Volatility Report & Risk Managed Investment Signals - Newser
Palvella Therapeutics (NASDAQ:PVLA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock keep high P E multiplesMarket Growth Summary & Risk Managed Trade Strategies - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $117.33 Consensus PT from Brokerages - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.9%Should You Sell? - MarketBeat
Tech Rally: How risky is Palvella Therapeutics Inc stock now2025 Geopolitical Influence & Technical Entry and Exit Tips - BỘ NỘI VỤ
Palvella Therapeutics (PVLA) Stock Analysis Report | Financials & Insights - Benzinga
Will Palvella Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tiny Biotech’s Big Bet On Rare Skin Diseases - Finimize
Will Palvella Therapeutics Inc. stock continue upward momentumJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - BỘ NỘI VỤ
Palvella Therapeutics stock hits 52-week high at 104.99 USD By Investing.com - Investing.com Australia
Palvella Therapeutics stock hits 52-week high at 104.99 USD - Investing.com India
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):